A recently published study(Xin et al.,Prog Biochem Biophys,2026,53(2):431-441.DOI:10.3724/j.pibb.2025.0508)addresses the therapeutic challenges of pancreatic ductal adenocarcinoma(PDAC)by innovatively developing an or...A recently published study(Xin et al.,Prog Biochem Biophys,2026,53(2):431-441.DOI:10.3724/j.pibb.2025.0508)addresses the therapeutic challenges of pancreatic ductal adenocarcinoma(PDAC)by innovatively developing an orally administered nanogene delivery system.Designed to achieve in situ,efficient delivery of chimeric antigen receptor(CAR)genes to tumor sites,this approach offers a novel strategy for CAR-macrophage(CAR-M)based immunotherapy.Its key highlights are as follows.展开更多
Aerodynamic research on road cars was reviewed in this work under the thread of reducing drag,with the awareness that this may succeed in effectively decreasing the carbon footprint of transportation.First,a selection...Aerodynamic research on road cars was reviewed in this work under the thread of reducing drag,with the awareness that this may succeed in effectively decreasing the carbon footprint of transportation.First,a selection of studies was presented to focus on the most important aerodynamic features of the flow around realistic car body shapes.Then,the discussion was organized around three pillars related to passive flow control,active flow control and active aerodynamics.Both experimental and numerical investigations were included to provide a comprehensive overview.A clear distinction was made between simplified and realistic car models,as well as production vehicles(within the limits of restricted access information).Moreover,a short essay was dedicated to electric vehicles,for which aerodynamics matters,especially at highway speeds.Last,the impact of aerodynamic principles on the design of current and future vehicle fleet was assessed,honestly admitting that recent market trends must be reversed to turn decarbonization goals into reality and damp the effects of global warming.展开更多
The paradigm of cancer treatment has been reshaped by chimeric antigen receptor(CAR)αβT cell therapy,yet its full potential remains constrained by fundamental limitations.While conventional CARαβT cells have achie...The paradigm of cancer treatment has been reshaped by chimeric antigen receptor(CAR)αβT cell therapy,yet its full potential remains constrained by fundamental limitations.While conventional CARαβT cells have achieved notable success in hematological malignancies,their broader application is hindered by the high cost and delays of autologous manufacturing,as well as the critical risk of graft-vs-host disease(GvHD).In addition,their efficacy against solid tumors is often compromised by the immunosuppressive tumor microenvironment(TME).As a promising solution,γδT cells are being developed as an alternative CAR platform.Their intrinsic ability to recognize transformed cells in a major histocompatibility complex(MHC)-independent manner minimizes the risk of GvHD and supports the creation of safe,effective allogeneic therapies.Building on this unique biology,the therapeutic efficacy of CARγδT cells is being enhanced through advanced engineering strategies.Key innovations include“armoring”technologies,such as cytokine secretion,checkpoint blockade,and metabolic rewiring,to overcome local immunosuppression and improve persistence,as well as the use of induced pluripotent stem cells(iPSCs)to generate standardized products from a renewable and consistent source.This expanding technological toolbox is also enabling novel applications beyond oncology.For example,chimeric autoantibody receptor(CAAR)constructs built onγδT cells integrate both classical and emerging insights into CARγδT cell therapy,highlighting innovations that are driving the field toward safer,more versatile,and longer-lasting treatments for cancer and autoimmunity.In light of these advancements,this review provides an overview of the current understanding ofγδT cell biology and highlights emerging engineering strategies that enhance the efficacy and durability of CARγδT cells across oncologic and autoimmune contexts.展开更多
With the theme of“standardized approaches empowering industrial green and low-carbon transformation”,a sub-forum was held to promote the application of the carbon footprint management system in China,advance the wid...With the theme of“standardized approaches empowering industrial green and low-carbon transformation”,a sub-forum was held to promote the application of the carbon footprint management system in China,advance the wide implementation of relevant standards,and accelerate the globalization process of green product trade through high-level communication.Lyu Xuefeng,Director of Qingdao Institute of Bioenergy and Bioprocess Technology(QIBEBT),Chinese Academy of Sciences,emphasized in his address that the product carbon footprint management system is the important support for industrial green transformation.The geographic information system-life cycle assessment(GIS-LCA)technology has been originally proposed and adopted as the core content of the national standard GB/T 24067-2024,Greenhouse gases-Carbon footprint of products-Requirements and guidelines for quantification.展开更多
多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤,尽管新型蛋白酶体抑制剂、免疫调节剂及CD38单抗等药物的应用显著延长了患者的生存时间,但复发耐药仍难以避免。细胞免疫治疗,特别是嵌合抗原受体(chimeric antigen...多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤,尽管新型蛋白酶体抑制剂、免疫调节剂及CD38单抗等药物的应用显著延长了患者的生存时间,但复发耐药仍难以避免。细胞免疫治疗,特别是嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法的快速发展,极大程度的改变了复发/难治性(relapsed/refractory,R/R)MM患者的治疗现状。FDA目前已批准了2款靶向B细胞成熟抗原(B cell maturation antigen,BCMA)的CAR-T细胞产品,使其用于既往接受过4线及以上治疗的R/R MM患者。随着临床研究的不断深入,靶向GPRC5D(G protein-coupled receptor C class Group 5 member D,G蛋白偶联受体C类第5组成员D)的CAR-T细胞治疗也显示出其独特的优势。除了应用于难治复发的患者,多项临床试验支持CAR-T在MM中治疗线数的前移。本文就CAR-T细胞治疗在MM中开展的关键性临床研究展开综述,旨在为临床应用提供参考。展开更多
文摘A recently published study(Xin et al.,Prog Biochem Biophys,2026,53(2):431-441.DOI:10.3724/j.pibb.2025.0508)addresses the therapeutic challenges of pancreatic ductal adenocarcinoma(PDAC)by innovatively developing an orally administered nanogene delivery system.Designed to achieve in situ,efficient delivery of chimeric antigen receptor(CAR)genes to tumor sites,this approach offers a novel strategy for CAR-macrophage(CAR-M)based immunotherapy.Its key highlights are as follows.
文摘Aerodynamic research on road cars was reviewed in this work under the thread of reducing drag,with the awareness that this may succeed in effectively decreasing the carbon footprint of transportation.First,a selection of studies was presented to focus on the most important aerodynamic features of the flow around realistic car body shapes.Then,the discussion was organized around three pillars related to passive flow control,active flow control and active aerodynamics.Both experimental and numerical investigations were included to provide a comprehensive overview.A clear distinction was made between simplified and realistic car models,as well as production vehicles(within the limits of restricted access information).Moreover,a short essay was dedicated to electric vehicles,for which aerodynamics matters,especially at highway speeds.Last,the impact of aerodynamic principles on the design of current and future vehicle fleet was assessed,honestly admitting that recent market trends must be reversed to turn decarbonization goals into reality and damp the effects of global warming.
基金supported by the National Research Foundation of Korea(NRF)through the Ministry of Education(2021R1I1A3059820)(to Jea-Hyun Baek).
文摘The paradigm of cancer treatment has been reshaped by chimeric antigen receptor(CAR)αβT cell therapy,yet its full potential remains constrained by fundamental limitations.While conventional CARαβT cells have achieved notable success in hematological malignancies,their broader application is hindered by the high cost and delays of autologous manufacturing,as well as the critical risk of graft-vs-host disease(GvHD).In addition,their efficacy against solid tumors is often compromised by the immunosuppressive tumor microenvironment(TME).As a promising solution,γδT cells are being developed as an alternative CAR platform.Their intrinsic ability to recognize transformed cells in a major histocompatibility complex(MHC)-independent manner minimizes the risk of GvHD and supports the creation of safe,effective allogeneic therapies.Building on this unique biology,the therapeutic efficacy of CARγδT cells is being enhanced through advanced engineering strategies.Key innovations include“armoring”technologies,such as cytokine secretion,checkpoint blockade,and metabolic rewiring,to overcome local immunosuppression and improve persistence,as well as the use of induced pluripotent stem cells(iPSCs)to generate standardized products from a renewable and consistent source.This expanding technological toolbox is also enabling novel applications beyond oncology.For example,chimeric autoantibody receptor(CAAR)constructs built onγδT cells integrate both classical and emerging insights into CARγδT cell therapy,highlighting innovations that are driving the field toward safer,more versatile,and longer-lasting treatments for cancer and autoimmunity.In light of these advancements,this review provides an overview of the current understanding ofγδT cell biology and highlights emerging engineering strategies that enhance the efficacy and durability of CARγδT cells across oncologic and autoimmune contexts.
文摘With the theme of“standardized approaches empowering industrial green and low-carbon transformation”,a sub-forum was held to promote the application of the carbon footprint management system in China,advance the wide implementation of relevant standards,and accelerate the globalization process of green product trade through high-level communication.Lyu Xuefeng,Director of Qingdao Institute of Bioenergy and Bioprocess Technology(QIBEBT),Chinese Academy of Sciences,emphasized in his address that the product carbon footprint management system is the important support for industrial green transformation.The geographic information system-life cycle assessment(GIS-LCA)technology has been originally proposed and adopted as the core content of the national standard GB/T 24067-2024,Greenhouse gases-Carbon footprint of products-Requirements and guidelines for quantification.
文摘多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的血液系统恶性肿瘤,尽管新型蛋白酶体抑制剂、免疫调节剂及CD38单抗等药物的应用显著延长了患者的生存时间,但复发耐药仍难以避免。细胞免疫治疗,特别是嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法的快速发展,极大程度的改变了复发/难治性(relapsed/refractory,R/R)MM患者的治疗现状。FDA目前已批准了2款靶向B细胞成熟抗原(B cell maturation antigen,BCMA)的CAR-T细胞产品,使其用于既往接受过4线及以上治疗的R/R MM患者。随着临床研究的不断深入,靶向GPRC5D(G protein-coupled receptor C class Group 5 member D,G蛋白偶联受体C类第5组成员D)的CAR-T细胞治疗也显示出其独特的优势。除了应用于难治复发的患者,多项临床试验支持CAR-T在MM中治疗线数的前移。本文就CAR-T细胞治疗在MM中开展的关键性临床研究展开综述,旨在为临床应用提供参考。
